Saez-Llorens X, Castrejon Alba MM, Guerra EC, McClemon DR, Gilbert CA, McCoig CC, Ramilo O; International Conference on AIDS.
Int Conf AIDS. 1998; 12: 62 (abstract no. 12252).
Hospital del Nino Servicio Infectiologia Arda. Balboa Panama.
BACKGROUND AND METHODS: This study was designed to compare the effect of 3TC/ZDV/ABC vs. 3TC/ZDV on CSF viral load and clinical manifestations of HIV encephalopathy in children. Viral load was assessed using the NASBA assay (Organon Teknika). RESULTS: 26 children were enrolled in this sub-study. At baseline, 21 (87%) had abnormal neurological findings, and 15 (58%) had abnormalities on brain CT scan. CSF samples were obtained at baseline, week (wk) 8 and wk 16. Of 23 patients evaluated at wk 0 and wk 8, 4 (17%) had undetectable (< 2.0 log) CSF viral load (VL) at both time points, while 10 (43%) dropped to undetectable after initiation of therapy. Thus, 14 (61%) had undetectable CSF VL at wk 8. As shown below, patients who dropped to undetectable at wk 8 had lower baseline CSF VL and larger VL reductions than those who remained detectable. Whether these differences are attributable to treatment with abacavir is unknown since the study is currently blinded. Unblinded VL results from wk 0, 8 and 16 and genotypic analysis of the HIV RT gene will be presented. TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSIONS: Combination therapy with 3TC/ZDV with or without abacavir reduces CSF Viral load in HIV-infected children. Unblinding of the study will reveal whether addition of abacavir results in greater VL reduction than seen with ZDV/3TC alone.
Publication Types:
Keywords:
- AIDS Dementia Complex
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Anti-HIV Agents
- Child
- Dideoxynucleosides
- Government Agencies
- HIV
- HIV Infections
- HIV Protease Inhibitors
- HIV Seropositivity
- Humans
- Lamivudine
- Viral Load
- Zidovudine
- abacavir
- organization & administration
Other ID:
UI: 102227280
From Meeting Abstracts